Literature DB >> 25842992

Renal damage detected by DMSA, despite normal renal ultrasound, in children with febrile UTI.

N C Bush1, M Keays2, C Adams3, K Mizener4, K Pritzker3, W Smith3, J Traylor3, C Villanueva5, W T Snodgrass6.   

Abstract

OBJECTIVES: 2011 American Academy of Pediatrics guidelines recommended renal-bladder ultrasound (RBUS) as the only evaluation after febrile urinary tract infection (FUTI) in infants aged 2-24 months. We determined the sensitivity, specificity, and false negative rate of RBUS to identify DMSA-detected renal damage in this age group as well as in older children.
METHODS: Consecutive patients referred to pediatric urology with a history of FUTI underwent DMSA ≥ 3 months after FUTI. Abnormal RBUS was defined as: Society of Fetal Urology hydronephrosis grades I-IV; hydroureter ≥ 7 mm; renal scar defined as focal parenchymal thinning; and/or size discrepancy ≥ 1 cm between kidneys. Abnormal DMSA was presence of any focal uptake defects and/or split renal function < 44%. We calculated sensitivity, specificity, positive and negative predictive values, and false negative rates of RBUS compared to DMSA.
RESULTS: 618 patients (79% female), median age 3.4 years, were referred for FUTIs. Of the 512 (83%) with normal RBUS, 99 (19%) had abnormal DMSA. Children with normal RBUS after their first FUTI had abnormal DMSA in 15/151 (10%) aged ≤ 24 months and 23/119 (19%) aged > 24 months. RBUS had poor sensitivity (34%) and low positive predictive value (47%) to identify patients with renal damage. 99/149 (66%) children with renal damage on DMSA had normal RBUS.
CONCLUSION: After FUTI, 66% of children with reduced renal function and/or renal cortical defects found by DMSA scintigraphy had a normal RBUS. Since abnormal DMSA may correlate with increased risk for VUR, recurrent FUTI and renal damage, our data suggest RBUS alone will fail to detect a significant proportion of patients at risk. The data suggest that imaging after FUTI should include acute RBUS and delayed DMSA, reserving VCUG for patients with abnormal DMSA and/or recurrent FUTI.
Copyright © 2015 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  DMSA; Renal ultrasonography; UTI; VUR

Mesh:

Substances:

Year:  2015        PMID: 25842992     DOI: 10.1016/j.jpurol.2015.01.011

Source DB:  PubMed          Journal:  J Pediatr Urol        ISSN: 1477-5131            Impact factor:   1.830


  7 in total

Review 1.  [Imaging in urinary tract infections in childhood].

Authors:  B Zieger
Journal:  Radiologe       Date:  2016-11       Impact factor: 0.635

2.  Delayed diagnosis of primary vesicoureteral reflux in children with recurrent urinary tract infections: Diagnostic approach and renal outcomes.

Authors:  Çağla Serpil Doğan; Nevin Semerci Koyun; Gülşah Kaya Aksoy; Bülent Çekiç; Murat Savaş; Elif Çomak
Journal:  Turk J Urol       Date:  2018-11

3.  Comparison of Urinary Tract Dilatation and Society of Fetal Urology systems in the detection of vesicourethral reflux and renal scar.

Authors:  Gulec Mert Dogan; Ahmet Sigirci; Aslinur Cengiz; Sevgi Demiroz Tasolar; Turan Yildiz; Yilmaz Tabel; Ahmet Taner Elmas; Muge Otlu; Sait Murat Dogan
Journal:  Pol J Radiol       Date:  2021-07-23

4.  Urinary tract infection in small children: the evolution of renal damage over time.

Authors:  Svante Swerkersson; Ulf Jodal; Rune Sixt; Eira Stokland; Sverker Hansson
Journal:  Pediatr Nephrol       Date:  2017-07-05       Impact factor: 3.714

Review 5.  Imaging studies and biomarkers to detect clinically meaningful vesicoureteral reflux.

Authors:  Michaella Maloney Prasad; Earl Y Cheng
Journal:  Investig Clin Urol       Date:  2017-05-24

Review 6.  Critical appraisal of the top-down approach for vesicoureteral reflux.

Authors:  Ahmed Abdelhalim; Antoine E Khoury
Journal:  Investig Clin Urol       Date:  2017-05-31

Review 7.  The Management of the Pediatric Neurogenic Bladder.

Authors:  Renea M Sturm; Earl Y Cheng
Journal:  Curr Bladder Dysfunct Rep       Date:  2016-07-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.